This functional assay reinforces our proposal that excessive expression of PIR may be a crucial event in tumorigenesis by conferring tumor cells resistance to immune clearance, suggesting that PIR is an emerging target for cancer immune therapy. This evidence concerns the gene PIR and neoplasm.